Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

While the National Treasury has released R700m, the Bill and Melinda Gates Foundation and the Wellcome Trust will ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

National Treasury has allocated R753 million to the Department of Health -- under Section 16 of the Public Finance Management ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...